Rescuing a Rare Disease Trial: Accelerating MRCT RA Submissions for a Taiwan Biotech Company
This case study highlights HiRO's effective intervention in accelerating the regulatory submission process for a…
Article Date
January 29, 2026
This article is featured on another website.
Go to article
March 10, 2026
Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
March 10, 2026
Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
March 3, 2026
HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment
SOMERSET, N.J., March 3, 2026 -- Harvest Integrated Research Organization (HiRO), a global contract research…
March 3, 2026
HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment
SOMERSET, N.J., March 3, 2026 -- Harvest Integrated Research Organization (HiRO), a global contract research…